- Home
- SLNO
as 10-22-2024 4:00pm EST
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 1.9B | IPO Year: | 2014 |
| Target Price: | $68.71 | AVG Volume (30 days): | 803.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.30 - $56.81 | Next Earning Date: | 11-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Soleno Therapeutics Inc. (SLNO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Anish Bhatnagar | SLNO | CHIEF EXECUTIVE OFFICER | Oct 1 '24 | Sell | $49.79 | 21,633 | $1,069,306.22 | 719,553 | |
| Yen Kristen | SLNO | SEE REMARKS | Oct 1 '24 | Sell | $49.79 | 3,108 | $153,626.63 | 81,465 | |
| Mackaness James H | SLNO | CHIEF FINANCIAL OFFICER | Aug 28 '24 | Sell | $47.55 | 13,531 | $641,782.70 | 128,524 | |
| Anish Bhatnagar | SLNO | CHIEF EXECUTIVE OFFICER | Aug 28 '24 | Sell | $47.55 | 115,004 | $5,454,707.25 | 719,553 | |
| Yen Kristen | SLNO | SEE REMARKS | Aug 28 '24 | Sell | $47.55 | 10,705 | $507,744.55 | 81,465 | |
| Hirano Patricia C | SLNO | SEE REMARKS | Aug 28 '24 | Sell | $47.55 | 10,705 | $507,744.55 | 119,928 | |
| Vivo Opportunity, LLC | SLNO | 10% Owner | Aug 27 '24 | Sell | $47.77 | 1,025,000 | $49,210,750.00 | 6,816,851 | |
| Mackaness James H | SLNO | CHIEF FINANCIAL OFFICER | Aug 5 '24 | Sell | $45.28 | 14,983 | $683,201.60 | 128,524 | |
| Anish Bhatnagar | SLNO | CHIEF EXECUTIVE OFFICER | Aug 5 '24 | Sell | $45.28 | 127,344 | $5,806,696.14 | 719,553 | |
| Yen Kristen | SLNO | SEE REMARKS | Aug 5 '24 | Sell | $45.28 | 10,974 | $500,398.37 | 81,465 |
Latest Soleno Therapeutics Inc. News
SLNO Breaking Stock News: Dive into SLNO Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.
Barrons.com
4 days ago
TriMas, Soleno Therapeutics, Ring Energy, and More Stocks See Action From Activist Investors
Insider Monkey
7 days ago
Soleno Therapeutics (SLNO): Pioneering Treatment for Prader-Willi Syndrome with DCCR
Insider Monkey
7 days ago
Soleno Therapeutics (SLNO): Breakthroughs in Prader-Willi Syndrome Treatment
GuruFocus.com
12 days ago
Carlyle Group Inc.'s Strategic Reduction in Soleno Therapeutics Inc.
Zacks
14 days ago
SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA
Motley Fool
14 days ago
Why Soleno Therapeutics Stock Blasted 9% Higher Today
MT Newswires
15 days ago
Soleno Therapeutics Says US FDA Determines NDA for DCCR Does Not Need Advisory Panel Meeting for Now
Compare SLNO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLNO Soleno Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.